Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Int J Mol Sci. 2020 Jan 19;21(2):649. doi: 10.3390/ijms21020649.
Since the discovery of the first microRNA (miRNA) decades ago, studies of miRNA biology have expanded in many biomedical research fields, including eye research. The critical roles of miRNAs in normal development and diseases have made miRNAs useful biomarkers or molecular targets for potential therapeutics. In the eye, ocular neovascularization (NV) is a leading cause of blindness in multiple vascular eye diseases. Current anti-angiogenic therapies, such as anti-vascular endothelial growth factor (VEGF) treatment, have their limitations, indicating the need for investigating new targets. Recent studies established the roles of various miRNAs in the regulation of pathological ocular NV, suggesting miRNAs as both biomarkers and therapeutic targets in vascular eye diseases. This review summarizes the biogenesis of miRNAs, and their functions in the normal development and diseases of the eye, with a focus on clinical and experimental retinopathies in both human and animal models. Discovery of novel targets involving miRNAs in vascular eye diseases will provide insights for developing new treatments to counter ocular NV.
自几十年前发现第一个 microRNA (miRNA) 以来,miRNA 生物学的研究在许多医学研究领域都得到了扩展,包括眼部研究。miRNAs 在正常发育和疾病中的关键作用使它们成为潜在治疗药物的有用生物标志物或分子靶标。在眼睛中,眼新生血管化 (NV) 是多种血管性眼病致盲的主要原因。目前的抗血管生成疗法,如抗血管内皮生长因子 (VEGF) 治疗,存在其局限性,这表明需要研究新的靶点。最近的研究确立了各种 miRNAs 在病理性眼部 NV 调控中的作用,提示 miRNAs 既是血管性眼病的生物标志物,也是治疗靶点。本综述总结了 miRNAs 的生物发生及其在眼部正常发育和疾病中的功能,重点介绍了人类和动物模型中临床和实验性视网膜病变。在血管性眼病中发现涉及 miRNAs 的新靶点,将为开发新的治疗方法以对抗眼部 NV 提供思路。